Investor IPR challenger fails for the 4th time

Court drug approval

Hedge fund manager Kyle Bass has gone on the offensive in recent months, challenging multiple pharma patents in court. The first three of his challenges were denied by the Patent Trial and Appeal Board, and the PTAB just denied his fourth attempt. Bass’s Ferrum Ferro Capital had brought a challenge against a patent for a glaucoma drug owned by Allergan.

Read the source article at

About the Author

Related Posts

Leave a Reply